Krajewski, Piotr K.
Strobel, Alexandra
Schultheis, Michael
Staubach, Petra
Grabbe, Stephan
Hennig, Katharina
Matusiak, Lukasz
von Stebut, Esther
Garcovich, Simone
Bayer, Hans
Heise, Marcus
Kirschner, Uwe
Nikolakis, Georgios
Szepietowski, Jacek C. http://orcid.org/0000-0003-0766-6342
Clinical trials referenced in this document:
Documents that mention this clinical trial
Profound Sexual Dysfunction Among Patients with Hidradenitis Suppurativa: A Cross-sectional Study
https://doi.org/10.1007/s13555-024-01196-y
Funding for this research was provided by:
ERA PerMed (Biomolecular Analyses for Tailored Medicine in AcneiNversa (BATMAN) project)
Article History
Received: 5 May 2024
Accepted: 24 May 2024
First Online: 13 June 2024
Declarations
:
: Michael Schultheis: Grants or contracts from any entity: LENICURA GmbH—auditor activity on the implementation of the contract “AOK-Priomed Acne inversa” | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events: UCB, Pfizer, AbbVie—honoraria for lectures | Support for attending meetings and/or travel: UCB,AbbVie, Pfizer, Almirall Novartis – funding of travel, congress, and hotel fees; Advisory Boards: UCB and Novartis. Stephan Grabbe: Grants or contracts from any entity: Novartis, Pierre Fabre | Consulting fees: AbbVie, BMS, MSD, Genzyme, Klinge Pharma, Sun Pharma, Kyowa-Kirin, Novartis, Pierre Fabre | Participation on a Data Safety Monitoring Board or Advisory Board: Alcedis | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid unrelated to current work presented here: DeCOG, German dermatological cooperative oncology group—unrelated to current work presented here. Petra Staubach: Grants or contracts from any entity: Novartis; Allmirall | Consulting fees: AbbVie, Allergika, Almirall-Hermal, Amgen, Beiersdorf, Biocryst, BMS, Boehringer-Ingelheim, Celgene, CSL-Behring, Eli Lilly, Falk, Galderma, Hexal, Janssen, Klinge, Klosterfrau, LEO-Pharma, LETI-Pharma, L’Oreal, Novartis, Octapharma, Pfizer, Pflüger, Pharming, Regeneron, Shire, Takeda, Sanofi-Genzyme, UCB Pharma | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid unrelated to current work presented here: Society of dermopharmazie, UNEV. Alexandra Strobel: Nothing to declare. Marcus Heise: Nothing to declare. Katharina Hennig: CEO and stakeholder of LENICURA GmbH. Georgios Nikolakis: Consulting fees—Dessau Medical Center received a consulting fee from Mölnlycke Health Care GmbH, for which I served as a consulting physician | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events: Speaker for the EADV HS Course 28–30.11.2022, Porto, Portugal | Support for attending meetings and/or travel: Elli Lilly Scholarship for attending EADV 2021 | Participation in a data protection monitoring board or advisory board—Dessau Medical Center received a consulting fee from Mölnlycke Health Care GmbH, for which I served as a consulting physician, travel grants from Abbvie. Uwe Kirschner: Consulting Fees: Novartis | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events: Novartis | Participation on a data protection monitoring board or advisory board: Novartis, EsmAiL, EpiCAi | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid: Deutsche Gesellschaft für Wundheilung und Wundbehandlung. Jacek C Szepietowski: Advisory Board/Consultant for AbbVie, Leo Pharma, Novartis, Pfizer, Sanofi-Genzyme, Trevi, UCB and Vifor; Speaker for AbbVie, Almirall, Janssen-Cilag, Eli Lilly, Leo Pharma, Novartis, Pfizer, Sanofi-Genzyme; Investigator for for AbbVie, Almirall, Amgen, AnaptysBio, BMS, Boehringer Ingelheim, Celtrion, Galderma, Galapagos, Helm AG, Kliniksa, Incyte, InfraRX, Janssen-Cilag, Leo Pharma, Medimmune, Menlo Therapeutics, Merck, Novartis, Pfizer, Regeneron, UCB, Teva, Trevi. Jacek C. Szepietowski is an Editorial Board member of<i> Dermatology and Therapy</i>. Jacek C. Szepietowski was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions.. Lukasz Matusiak: Advisory Board/Consultant for AbbVie, Novartis; Speaker for AbbVie, Aristo, Leo Pharma, Medac; Investigator for for AbbVie, Almirall, Amgen, AnaptysBio, BMS, Boehringer Ingelheim, Celtrion, Galderma, Galapagos, Helm AG, Kliniksa, Incyte, InfraRX, Janssen-Cilag, Leo Pharma, Medimmune, Menlo Therapeutics, Merck, Novartis, Pfizer, Regeneron, UCB, Teva, Trevi. Piotr Krajewski: Nothing to declare. Esther von Stebut: Consulting fees: Janssen, Novartis | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events: Janssen, Novartis, Infectopharm, Leo | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid: Deutsche Dermatologische Gesellschaft, Deutsche Forschungsgemeinschaft, Mediziner Fakultätentag). Hans Bayer, Simone Garcovich: No conflict of interest to this manuscript.
: The study was conducted following the Declaration of Helsinki and was approved by the Ethics Committee Rhineland-Palatinate ethics committee, and was registered with the German Register for Clinical Trials under the identifier DRKS00025315.